The Spanish Society of Neurology estimates that 600,000 people are affected by Alzheimer’s disease in this country.
Research Programmes / Core Facilities
Cell and Developmental Biology
Structural and Computational Biology
Chemistry and Molecular Pharmacology
Core Facilities & Services
Scientists at IRB Barcelona are supported by an extensive range of common core facilities that provide state-of-the-art technologies and scientific services. These facilities are a key asset for our research, allowing the Institute to obtain outstanding results. They are designed to incorporate the most novel technologies available and provide them to our researchers in the shortest time possible.
Selected IRB Barcelona publications
IRB Barcelona's partnerships, with organisations in areas of mutual interest and expertise, aim to take advantage of the wealth of knowledge, resources and technologies so critical to advancing the field of biomedicine
News & Events
New angles on Alzheimer’s disease
Researchers measure a property of DNA for the first time
Researchers identify a key molecule in flies that adjusts energy use under starvation conditions
The scientific community does not give up its fight against Alzheimer's disease
25SepStructural studies of gene editing machines
25SepStructural Characterization of Eukaryotic Translation Initiation at Atomic Resolution by Cryo-EM
25SepMulti-tasking Paneth(-like) cells: quiescent cancer stem cells, niche factors, and colon cancer susceptibility modifiers
25Sep1st LightSheet Fluorescence Microscopy International Conference & 6th LSFM International Workshop
The researchers have succeeded by using their own technique, recently developed at IBEC, based on electrostatic force microscopy (EFM).
Most scientific literature devoted to the protein p53 refers to cancer biology, and the functions of this molecule as a tumour suppressor have been described in detail.
At present, Alzheimer’s disease (AD) cannot be prevented, it is typically diagnosed only at an advances stage, and there is currently no drug on the market that can slow its progression.
Speaker: Dr. Laura Spagnolo,
University of Edinburgh, School of Biological Sciences, Institute of Structural Molecular Biology, UK
Speaker: Dr. Israel Sanchez,
MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, UK
Speaker: Riccardo Fodde,
PhD, Dept. of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands